Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Liraglutide: Selective GLP-1 receptor agonist with 97% homology to native GLP-1
2024 Jul 24;15:1431292
Side Effects Comparison# Retatrutide Side Effects# Phase 2 trial data revealed: Gastrointestinal : Nausea (24-46%), diarrhea (16-26%), vomiting (9-20%), constipation (6-16%) Heart rate : Small mean increase (2-4 bpm) potentially related to glucagon receptor activation Injection site reactions : Mild and transient Hepatic : Transient elevations in liver enzymes observed Discontinuation rate : 6-10% due to adverse events in Phase 2 The glucagon receptor component introduces a unique side effect profile compared to GLP-1-only or GIP/GLP-1 dual agonists
Not intended for use by persons under the age of 18
Energy Expenditure: Semaglutide GLP-1 also activates brown adipose tissue, which burns calories to produce heat, aiding in weight loss through increased energy expenditure
US$ 20.38
US$ 21.48
US$ 22.30
US$ 26.63
US$ 29.54
